Oruka Therapeutics (ORKA) director discloses no securities ownership

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. director Christopher Martin has filed an initial beneficial ownership report indicating that he does not beneficially own any of the company’s securities. The report, dated 12/11/2025, is filed by a single reporting person and confirms that no non-derivative or derivative securities of Oruka Therapeutics are beneficially owned.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Martin Christopher Nathan

(Last) (First) (Middle)

C/O ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/11/2025

3. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Paul Quinlan, as attorney-in-fact for Christopher Martin	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does this ownership filing reveal for Oruka Therapeutics (ORKA)?

The filing states that the reporting person, Christopher Martin, does not beneficially own any securities of Oruka Therapeutics, Inc., including both non-derivative and derivative securities.

Who is the reporting person in this Oruka Therapeutics (ORKA) insider filing?

The reporting person is Christopher Martin, as indicated by the signature by Paul Quinlan acting as attorney-in-fact for Christopher Martin.

What is Christopher Martin’s relationship to Oruka Therapeutics (ORKA)?

Christopher Martin is identified as a Director of Oruka Therapeutics, Inc. on the ownership report.

How many Oruka Therapeutics securities does Christopher Martin report owning?

The report includes an explanation of responses stating that No securities are beneficially owned, meaning he reports no beneficial ownership of Oruka Therapeutics securities.

What is the date of the event requiring this ownership statement for ORKA?

The date of the event requiring the statement is listed as 12/11/2025.

Is this Oruka Therapeutics ownership report filed by one or multiple reporting persons?

The document indicates that the form is filed by one reporting person, not by a group.